Tysabri
Biogen halts Tysabri trial after failure in acute ischemic stroke
February 8, 2018Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure
Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …
Biogen says European regulatory committee adopts positive view for Tysabri
June 1, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis
Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …
Perrigo pays $8.6 billion for Elan
July 30, 2013Research and Development, Sales and Marketing Elan, Perrigo, Tysabri
Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a bitter takeover battle that has …
Elan sceptical of Royalty
February 26, 2013Sales and Marketing Elan, FDA, Tysabri, royalty pharma
Elan Corporation has poured tepid water on private equity firm Royalty Pharma’s putative offer this week for the Irish biotech …
Genzyme MS drug approved in US
September 13, 2012Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis
US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …
Elan to spin off drug discovery arm
August 14, 2012Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis
Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …
In brief: European Medicines Agency news
January 26, 2010Research and Development, Sales and Marketing Arepanrix, Arzerra, EMEA, GSK, Tysabri
GlaxoSmithKline’s influenza vaccine Arepanrix has been granted conditional marketing authorisation in Europe under an emergency fast-track procedure.It is the fourth …
European regulators begin Tysabri review
October 26, 2009Sales and Marketing EU, Tysabri, reg
European regulators have begun a risk-benefit review of Biogen Idec’s multiple sclerosis drug Tysabri, which has been linked to 23 …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
